Outlook Therapeutics (OTLK) faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections and a ...

Emotions are constructed, not discovered. Relational safety—not precise labels—allows the brain to tolerate uncertainty, ...

Flood of unreality is an endpoint of algorithm-driven internet and product of an economy dependent on a few top tech firms ...

No, Microsoft is not rewriting Windows in Rust. The clarification comes after a LinkedIn post by a Microsoft Distinguished ...

In a quarterly report filed with the U.S. Securities and Exchange Commission on November 14, 2025 ( SEC filing ), TREMBLANT CAPITAL GROUP disclosed a new position in CyberArk Software Ltd.

Agios upgraded after FDA approval of Aqvesme for thalassemia. Explore AGIO’s financial outlook, upside potential, and future ...

Ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival (OS) in the phase ...

Explore the differences between passkeys and biometrics in authentication. Understand their functionalities, security, and how they enhance software development.

Explore the top antivirus solutions for Windows in 2025, focusing on comprehensive security, compliance, and resilience for enterprises in the evolving threat landscape.

The KINECT-DCP trial evaluated the efficacy and safety of valbenazine in patients with dyskinesia due to cerebral palsy who experience choreiform movements.

Lexaria says its oral GLP-1 cut total adverse events nearly 48% versus Novo's Rybelsus, with comparable HbA1c results in a Phase 1b study.

Millions of people in the U.S. and around the world are living with hepatitis C virus (HCV). But over the past decade, direct-acting antivirals (DAA) have proven effective against HCV, curing more ...